Showing results (101-110 of 117) with videos related to
Sort By:
Pageof 12
Urology|May 12, 2004
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer programPeter Iversen, Manfred P Wirth, William A See, et al.BJU International|November 20, 2014
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancerFatima H Karzai, Andrea B Apolo, Liang Cao, et al.Scientific Reports|March 31, 2022
Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progressionWilliam Gesztes, Cara Schafer, Denise Young, et al.International Journal of Radiation Oncology, Biology, Physics|February 28, 2003
Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease ResearchPeter A S Johnstone, Robert H Riffenburgh, Judd W Moul, et al.Cancer Research|May 2, 2018
Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell GrowthAhmed A Mohamed, Charles P Xavier, Gauthaman Sukumar, et al.Genes & Cancer|February 14, 2017
Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K GagAnshu Rastogi, Amina Ali, Shyh-Han Tan, et al.The Journal of Urology|July 20, 2002
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer programWilliam A See, Manfred P Wirth, David G McLeod, et al.Oncotarget|November 20, 2019
Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrenceWusheng Yan, Muhammad Jamal, Shyh-Han Tan, et al.European Urology Focus|July 30, 2017
Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient CohortJennifer Cullen, Denise Young, Yongmei Chen, et al.Journal of Translational Medicine|January 9, 2020
Multi-omic serum biomarkers for prognosis of disease progression in prostate cancerMichael A Kiebish, Jennifer Cullen, Prachi Mishra, et al.Pageof 12